Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

The brokerage industry regulator cited gaps in surveillance, customer due diligence, and red-flag escalation across the ...

A detailed to-do list for SEC-registered firms to build a foundation for compliant and effective anti-money laundering ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...

Two of the largest organizations representing investment advisers and asset managers are voicing support for a federal proposal to postpone new anti-money laundering requirements for RIAs, while ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia ...

In financial institutions across the United States, there’s a reflex that’s become almost ritual. When a regulator walks in, or a board member asks whether the AML program is working, the answer is ...

– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers – SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today ...